Lupus Serum IgG Induces Skin Inflammation through the TNFR1 Signaling Pathway

被引:51
作者
Deng, Guo-Min [1 ]
Liu, Lena [1 ]
Kyttaris, Vasileios C. [1 ]
Tsokos, George C. [1 ]
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
NECROSIS-FACTOR-ALPHA; CLINICAL-FEATURES; DENDRITIC CELLS; I INTERFERON; ERYTHEMATOSUS; DISEASE;
D O I
10.4049/jimmunol.0902514
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by high autoantibody levels and multiorgan tissue damage, including kidney and skin. Cutaneous manifestations are frequent in patients with SLE, yet the etiology and pathogenesis of skin injury in SLE remains unclear. We reasoned that lupus serum containing high levels of autoreactive Ig contributes to skin injury. In this article, we report that serum from SLE patients and lupus-prone mice induces skin inflammation following intradermal injection into normal mice. Lupus serum depleted of IgG failed to cause skin inflammation. Monocytes, but not lymphocytes, were found to be crucial in the development of lupus serum-induced skin inflammation, and lupus serum IgG induced monocyte differentiation into dendritic cells (DCs). TNF-alpha and TNFR1, but not TNFR2, were required for the development of lupus serum-induced skin inflammation. TNFR1, not TNFR2, represented the main molecule expressed in the skin lesions caused by injected lupus serum. Our studies demonstrated that lupus serum IgG causes skin injury by involving the TNFR1 signaling pathway and monocyte differentiation to DCs. Accordingly, disruption of the TNFR1-mediated signaling pathway and blockade of DC generation may prove to be of therapeutic value in patients with cutaneous lupus erythematosus. The Journal of Immunology, 2010, 184: 7154-7161.
引用
收藏
页码:7154 / 7161
页数:8
相关论文
共 21 条
[1]   The role of tumor necrosis factor-alpha in systemic lupus erythematosus [J].
Aringer, Martin ;
Smolen, Josef S. .
ARTHRITIS RESEARCH & THERAPY, 2008, 10 (01)
[2]   SYSTEMIC LUPUS-ERYTHEMATOSUS - CLINICAL AND IMMUNOLOGICAL PATTERNS OF DISEASE EXPRESSION IN A COHORT OF 1,000 PATIENTS [J].
CERVERA, R ;
KHAMASHTA, MA ;
FONT, J ;
SEBASTIANI, GD ;
GIL, A ;
LAVILLA, P ;
DOMENECH, I ;
AYDINTUG, AO ;
JEDRYKAGORAL, A ;
DERAMON, E ;
GALEAZZI, M ;
HAGA, HJ ;
MATHIEU, A ;
HOUSSIAU, F ;
INGELMO, M ;
HUGHES, GRV ;
CERVERA, R ;
SEBASTIANI, GD ;
FONT, J ;
KHAMASHTA, MA ;
HUGHES, GRV ;
FONT, J ;
CERVERA, R ;
LOPEZSOTO, A ;
VIVANCOS, J ;
INGELMO, M ;
URBANOMARQUEZ, A ;
KHAMASHTA, MA ;
VIANNA, J ;
HUGHES, GRV ;
GIL, A ;
LAVILLA, P ;
PINTADO, V ;
LOPEZDUPLA, M ;
VAZQUEZ, JJ ;
SEBASTIANI, GD ;
DERAMON, E ;
CAMPS, M ;
FRUTOS, MA ;
PERELLO, I ;
SANTOS, PG ;
ABARCA, M ;
NEBRO, AF ;
DOMENECH, I ;
TOKGOZ, G ;
AYDINTUG, AO ;
JEDRYKAGORAL, A ;
MALDYKOWA, H ;
CHWALINSKASADOWSKA, H ;
GALEAZZI, M .
MEDICINE, 1993, 72 (02) :113-124
[3]  
Crow MK, 2007, CURR TOP MICROBIOL, V316, P359
[4]   The cutaneous pathology of lupus erythematosus: a review [J].
Crowson, AN ;
Magro, G .
JOURNAL OF CUTANEOUS PATHOLOGY, 2001, 28 (01) :1-23
[5]   Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα [J].
Eriksson, C ;
Engstrand, S ;
Sundqvist, KG ;
Rantapää-Dahlqvist, S .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (03) :403-407
[6]   Autoantibodies and glomerulonephritis in systemic lupus erythematosus [J].
Fu, SM ;
Castillo, JD ;
Deshmukh, US ;
Lewis, JE ;
Waters, ST ;
Gaskin, F .
LUPUS, 2003, 12 (03) :175-180
[7]   Human and mouse plasmacytoid dendritic cells [J].
Hochrein, H ;
O'Keeffe, M ;
Wagner, H .
HUMAN IMMUNOLOGY, 2002, 63 (12) :1103-1110
[8]   Pathogenesis of cutaneous lupus erythematosus [J].
Kuhn, A. ;
Bijl, M. .
LUPUS, 2008, 17 (05) :389-393
[9]  
Kuhn Annegret, 2008, V10, P119, DOI 10.1159/000131451
[10]   Cutaneous lupus erythematosus: Understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies [J].
Lee, Henry J. ;
Sinha, Animesh A. .
AUTOIMMUNITY, 2006, 39 (06) :433-444